United StatesHealth

Kenvue (NYSE:KVUE) reported Q2 2026 net sales of $3.96 billion, up 3%, while diluted EPS increased to $0.24.

LifeMD (NASDAQ:LFMD) reported Q2 2026 revenue of $47.3 million and cut its full-year outlook after recording a $3.5 million adjusted EBITDA loss.

Moderna (NASDAQ:MRNA) received U.S. FDA approval for mFLUSIVA, an mRNA-based seasonal influenza vaccine for adults over 50.

Evotec (NASDAQ:EVO) entered a research partnership with Odyssey Therapeutics (NASDAQ:ODTX) to identify small-molecule candidates for autoimmune and inflammatory diseases.

Newmark (NASDAQ:NMRK) acquired L+P Immobilienbewertungs, adding more than 40 German valuation professionals, although the transaction’s financial terms were not disclosed.

Edgewell Personal Care (NYSE:EPC) reported fiscal third-quarter net sales of $570.1 million, up 1.7%, as North American organic sales returned to growth.

Elanco Animal Health (NYSE:ELAN) reported second-quarter revenue of $1.368 billion, up 10%, as Pet Health and Farm Animal sales increased.

CVS Health (NYSE:CVS) reported second-quarter revenues of $106.1 billion, representing a 7.3% increase driven by broad segment gains.

Lilly (NYSE:LLY) reported second-quarter revenue of $23 billion, up 48%, as demand for Mounjaro and Zepbound supported volume growth.

BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.705 billion, up 30%, as BRUKINSA sales expanded globally.

Pfizer (NYSE:PFE) reported second-quarter revenue of $15.03 billion, up 3%, while adjusted diluted earnings reached $0.77 per share.

IDEAYA Biosciences (NASDAQ:IDYA) said OptimUM-02 met its primary endpoint, extending median progression-free survival to 6.9 months from 3.1 months.